Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Revenue from the breast cancer treatment Verzenio also helped, climbing 36% to $1.55 billion. Overall, Lilly’s quarterly profit swelled to $4.41 billion. Revenue advanced 45% to $13.53 billion ...

That's where shoe inserts can offer additional support, says Kate Macfarlane, a certified running, fitness, and endurance coach. "They are typically used by runners requiring help to address ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

In particular, Lilly highlighted the momentum behind breast cancer med Verzenio and the SGLT2 inhibitor Jardiance, which generated roughly $1.6 billion and $1.2 billion in 2024’s fourth quarter ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

but one of the conclusions of the pilot was that a pre-requisite for adoption will be "robust systems in place ensuring that the patient can easily access the package leaflet for their medicine in ...

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...